AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, M. R.
Right arrow Articles by Khorakiwala, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, M. R.
Right arrow Articles by Khorakiwala, H. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3338-3342, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3338-3342.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of the New Quinolone WCK 771 against Staphylococci

Michael R. Jacobs,1* Saralee Bajaksouzian,1 Anne Windau,1 Peter C. Appelbaum,2 Mahesh V. Patel,3 Shrikant V. Gupte,3 Sachin S. Bhagwat,3 Noel J. De Souza,3 and Habil F. Khorakiwala3

Department of Pathology, Case Western Reserve University, Cleveland, Ohio,1 Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania,2 Wockhardt Research Center, Aurangabad, India3

Received 18 March 2004/ Returned for modification 10 April 2004/ Accepted 19 May 2004

The activity of WCK 771, an experimental quinolone developed to overcome quinolone resistance in staphylococci and other bacteria, was determined against quinolone-susceptible and -resistant Staphylococcus aureus and S. epidermidis. WCK 771 MICs for 50 and 90% of the strains tested (MIC50 and MIC90, respectively) were 0.008 and 0.015 µg/ml for S. aureus (n = 43) and 0.015 and 0.03 µg/ml for S. epidermidis (n = 44) for quinolone-susceptible isolates, compared to ciprofloxacin values of 0.12 and 0.25 µg/ml and 0.25 and 0.5 µg/ml, respectively. Values for levofloxacin were 0.12 and 0.25 µg/ml and 0.12 and 0.25 µg/ml, those for clinafloxacin were 0.015 and 0.03 µg/ml and 0.015 and 0.03 µg/ml, those for moxifloxacin were 0.03 and 0.06 µg/ml and 0.06 and 0.12 µg/ml, and those for gatifloxacin were 0.06 and 0.12 µg/ml and 0.12 and 0.25 µg/ml, respectively. The WCK 771 MIC50 and MIC90, respectively, were 0.5 and 1 µg/ml for both species of staphylococci (n = 73 for S. aureus, n = 70 for S. epidermidis) for isolates highly resistant to ciprofloxacin (MIC50 and MIC90, >32 and >32 µg/ml, respectively). Values for levofloxacin were 8 and 32 µg/ml and 8 and 32 µg/ml, those for clinafloxacin were 1 and 2 µg/ml and 0.5 and 2 µg/ml, those for moxifloxacin 4 and >4 µg/ml and 4 and >4 µg/ml, and those for gatifloxacin were 4 and >4 µg/ml and 2 and >4 µg/ml, respectively. WCK 771 and clinafloxacin demonstrated MICs of 1 µg/ml against three vancomycin-intermediate strains. WCK 771 showed concentration-independent killing for up to 24 h at 2, 4, and 8 times the MICs against quinolone-resistant staphylococci and was also bactericidal after 8 h for high-density inocula (108 CFU/ml) of quinolone-resistant strains at 5 µg/ml, whereas moxifloxacin at 7.5 µg/ml was bacteriostatic. WCK 771 was not a substrate of the NorA efflux pump as evident from the similar MICs against both an efflux-positive and an efflux-negative strain. Overall, WCK 771 was the most potent quinolone tested against the staphylococci tested, regardless of quinolone susceptibility.


* Corresponding author. Mailing address: Department of Pathology, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106. Phone: (216) 844-3484. Fax: (216) 844-5601. E-mail: mrj6{at}po.cwru.edu.


Antimicrobial Agents and Chemotherapy, September 2004, p. 3338-3342, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3338-3342.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.